



## Post Authorisation Assessments

### Cephacare Flavour 1000 mg Tablets for Dogs

Vm 32742/4027

•	19 March 2024	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). (NI) Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
•	09 October 2023	Deletion of a non-significant specification parameter in the specification parameters of the finished product. (GB)
•	12 June 2023	Minor changes to an approved test procedure for the finished product. (NI)
•	10 March 2023	Minor changes to an approved test procedure for the finished product. (GB)
•	11 August 2022	Change of MAH: from Animalcare Ltd, 10 Great North Way, York Business Park, Nether Poppleton, York, YO26 6RB, United Kingdom to Ecuphar NV, Legeweg 157-i, 8020 Oostkamp, Belgium.
•	06 May 2022	Change in the specification limits of the finished product.
•	18 February 2022	Renewal – UK as CMS.
•	27 January 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	12 June 2019	Changes to the packaging/package leaflet.
•	07 February 2019	Increase in the shelf-life of the finished product as packaged for sale, from 12 months to 36 months. Change in the specification limits of the finished product
•	23 October 2018	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS. Change of the back-up procedure of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	11 July 2018	Change in the number of units (tablets) in a pack outside the range of the currently approved pack sizes of the finished product.